Answers are grounded in this paper and cite their sources.
Chronic low-grade inflammation plays a pivotal role in the pathogenesis of coronary artery disease (CAD). We examined whether a modification of the INFLA score , combined with multi-omics data, could identify inflammation-associated proteins and metabolic pathways associated with CAD. Based on the heterogeneous performance of individual components, platelet count was excluded to derive an exploratory modification of the INFLA-CAD score, whose association with CAD risk was then evaluated using multivariable Cox models. Transcriptomic analysis of peripheral blood mononuclear cells (PBMCs), plasma proteomics, and Mendelian randomization were conducted to identify candidate inflammation-associated proteins. Metabolomic profiling and pathway enrichment analyses were used to investigate the metabolic signatures underlying inflammation and CAD risk. In vitro experiments using human umbilical vein endothelial cells (HUVECs) were further performed to determine the pathogenic effects of recombinant MERTK and to elucidate its potential underlying mechanisms. An exploratory modification of the score, the INFLA-CAD score, was associated with CAD risk (HR = 1.08, 95% CI 1.05–1.10 per SD, P < 0.001), with estimates similar to those of the original score and overlapping confidence intervals. Stratified analysis revealed that the association between INFLA-CAD score and CAD was stronger in individuals with high CAD polygenic risk (HR = 1.11, 95%CI:1.06–1.17, P < 0.001), suggesting a synergistic effect between genetic predisposition and inflammatory burden. Plasma MERTK was higher in individuals who subsequently developed CAD in minimally adjusted analyses, but this difference was attenuated to the null after adjustment for conventional risk factors; its correlation with the INFLA-CAD score was very weak ( R = 0.029), and it was not significantly correlated with the original INFLA score. MERTK mRNA was upregulated in PBMCs from patients with CAD. Mendelian randomisation results from a published plasma proteome atlas were consistent with an association between genetically predicted MERTK levels and multiple CAD-related outcomes. Exploratory enrichment analysis implicated the valine, leucine and isoleucine metabolic pathways. Consistently, elevated plasma MERTK levels were observed in both murine models of atherosclerosis and acute myocardial infarction. Recombinant MERTK impaired endothelial function in HUVECs, resulting in reduced migration, proliferation, and angiogenic activity. MERTK stimulation and CAV1 silencing converged on the same endothelial transcriptional programme, indicating that CAV1 lies on the MERTK-responsive pathway rather than demonstrating a directional dependency. A composite low-grade inflammation score was associated with CAD risk. Plasma MERTK was higher before CAD diagnosis in minimally adjusted analyses, but it did not remain associated after full adjustment, and its correlation with the INFLA-CAD score was weak ( R = 0.029). MERTK was linked to BCAA metabolic dysregulation and endothelial dysfunction through a CAV1-associated RTK–RAS–MAPK/ERK/PI3K programme, identifying it as a mechanistic candidate rather than an independent early biomarker. Not applicable.
No takes yet. Share an insight, caveat, or question.
Sheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: